BTK Degrader Innovation
Roche and Nurix Unveil $700M Deal for Brain-Penetrant BTK Degrader
Roche and Nurix Therapeutics have announced a global licensing and collaboration to co-develop and co-commercialize bexobrutideg (NX-5948), an oral BTK degrader, in the United States while Roche commercializes outside the U.S., with total deal value potentially reaching $2.3 billion. Nurix will receive a $700 million upfront payment and additional development, regulatory, and sales milestones, while development costs are split 40% for Nurix and 60% for Roche. The companies plan to share U.S. commercialization profits and losses equally, and Nurix is expected to earn tiered royalties in the high-teens to low-teens range on ex-U.S. sales. Roche frames bexobrutideg’s differentiated mechanism—degrading the BTK protein rather than only inhibiting its kinase activity—as a potential way to overcome resistance seen with existing BTK inhibitor therapies. The collaboration targets expansion beyond B-cell malignancies into immunology and neurology, including plans for a Phase 3 trial in second-line CLL beginning in summer 2026 and exploration of combination regimens. The agreement is expected to close in the third quarter of 2026, pending antitrust review.
Key Points
Bexobrutideg is described as a "brain-penetrant" oral BTK degrader that penetrates the blood-brain barrier, which the companies cited as part of why it is being pursued beyond oncology—specifically including multiple sclerosis (MS) and chronic spontaneous urticaria (CSU) alongside hematological cancers.
Roche and other coverage emphasized that bexobrutideg does more than block BTK activity: by degrading the BTK protein, it is designed to eliminate both BTK’s kinase and scaffolding functions (not just its enzymatic activity).
Roche Chief Medical Officer Levi Garraway said, "We believe bexobrutideg could represent a major leap forward in the fight against complex blood cancers and other diseases," tying the deal to a broader clinical ambition beyond CLL.
Legal/structural terms were detailed in a regulatory filing: Nurix granted Roche an exclusive worldwide license under certain Nurix IP rights, with Roche holding primary responsibility for certain regulatory, manufacturing, and commercialization activities (while Nurix retains participation rights in the U.S.). The collaboration is set to become effective upon the expiration of the applicable Hart-Scott-Rodino waiting period.
One report provided BTK-market context—listing key existing therapies and noting that Brukinsa generated about $3.9 billion in global sales during 2025—framing the competitive landscape the collaboration is targeting.
Sentiment
Mostly PositivePublishers
15
Articles
35
Reach
50
